Altavant   Report issue

For profit Phase 1 Phase 2
Founded: Cary NC United States (2018)
Status: Acquired by Sumitomo Dainippon (2019)

Organization Overview

First Clinical Trial
2019
NCT03924154
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Altavant Sciences GmbH | Altavant Sciences, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

intepirdine (1 trial)

rodatristat ethyl (5 trials)

Drugs in Phase 1 Trials (1)

moxifloxacin (avelox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Familial Primary Pulmonary Hypertension (Phase 2)

Hypertension (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 3